Armstrong Fleming & Moore Inc Increases Stake in Eli Lilly and Company $LLY

Armstrong Fleming & Moore Inc increased its holdings in Eli Lilly and Company (NYSE:LLY) by 196.5% in the second quarter, Holdings Channel.com reports. The firm owned 756 shares of the company’s stock after acquiring an additional 501 shares during the period. Armstrong Fleming & Moore Inc’s holdings in Eli Lilly and Company were worth $590,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Wedge Capital Management L L P NC lifted its position in shares of Eli Lilly and Company by 13.9% in the 1st quarter. Wedge Capital Management L L P NC now owns 738 shares of the company’s stock worth $610,000 after purchasing an additional 90 shares during the period. Covestor Ltd lifted its position in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after purchasing an additional 3,696 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Morgan Stanley dropped their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. Guggenheim raised their target price on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Cantor Fitzgerald lowered their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $943.00.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $845.55 on Thursday. The firm has a 50 day moving average of $738.69 and a 200 day moving average of $766.57. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $800.28 billion, a price-to-earnings ratio of 55.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.